On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has ...

Parents in Kerala concerned about changes in 'Mittayi' scheme for children with Type 1 diabetes, facing insulin issues.

Cash position of €7.1 million as of June 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 Current ...

Engineers at Georgia Tech developed a new mode of delivery for injectable medications — an 'exploding' capsule.

The shares of the prominent pharmaceutical company gained up to 4 percent in today's trading session after the company ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin aspart-xjhz, as a 3 mL single-patient-use prefilled pen and 10 mL multiple-dose ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Biocon Biologics on Wednesday said it has received approval from the US health regulator to market a diabetes treatment medication. The company, a unit of Biocon Ltd, has received approval from the US ...

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received approval from the U.S. Food and Drug Administration (FDA) for ...

Biocon bagged US FDA's approval for Kristy, which is a rapid-acting human insulin analog, indicated to improve glycemic ...